Cox regression | Hazard | (95 % CI) | Univariate P | Multivariate P |
---|---|---|---|---|
Age | 1.02 | (1.00–1.04) | 0.239 | |
Sex‘ | 0.76 | (0.50–1.14) | 0.179 | |
Karnofsky index | 0.98 | (0.95–0.99) | 0.014* | 0.037** |
Resection/RFA‘ | 0.90 | (0.56–1.44) | 0.658 | |
Oxaliplatin + 5-FU‘ | 1.44 | (0.91–2.26) | 0.118 | |
Irinotecan + 5-FU‘ | 1.41 | (0.82–2.46) | 0.216 | |
Capecitabine‘ | 1.24 | (0.79–1.94) | 0.344 | |
Bevacizumab‘ | 0.87 | (0.58–1.30) | 0.492 | |
Cetuximab‘ | 1.26 | (0.85–1.87) | 0.243 | |
Overall chemotherapy lines | 1.14 | (0.94–1.37) | 0.179 | |
UICC staging | 1.01 | (0.79–1.30) | 0.286 | |
Tumor grading | 0.90 | (0.64–1.28) | 0.434 | |
Lung metastases‘ | 1.53 | (0.85–2.74) | 0.155 | |
Lymphatic metastases‘ | 1.60 | (0.91–2.80) | 0.100* | 0.204 |
Bone metastases‘ | 2.51 | (0.89–7.13) | 0.083* | 0.083 |
Hepatic tumor load | 1.05 | (1.03–1.06) | <0.001* | 0.001** |
CEA serum level | 1.00 | (1.00–1.00) | 0.002* | 0.023** |
CA19-9 serum level | 1.00 | (1.00–1.00) | <0.001* | <0.001** |
Bilobar Y90 RE‘ | 0.89 | (0.45–1.77) | 0.740 | |
Unilobar Y90 RE‘ | 0.74 | (0.35–1.55) | 0.426 | |
Sequential lobar Y90 RE‘ | 0.82 | (0.40–1.66) | 0.775 | |
Y90 RE sessions per patient | 0.95 | (0.72–1.24) | 0.692 | |
Total activity per patient | 1.00 | (0.99–1.00) | 0.276 |